A minority subpopulation of CD133+/EGFRvIII+/EGFR- cells acquires stemness and contributes to gefitinib resistance

CNS Neuroscience and Therapeutics

Volumn 19, Issue 7, 2013, Pages 494-502

  Liu, Xu Jie ^a   Wu, Wen Tao ^a   Wu, Wei Hua ^a   Yin, Feng ^b   Ma, Si Hai ^c   Qin, Jia Zhen ^b   Liu, Xiu Xiu ^a   Liu, Yi Nan ^a   Zhang, Xiao Yan ^a   Li, Peng ^a   Han, Shuo ^a   Liu, Kai Yu ^a   Zhang, Jin Ming ^b   He, Qi Hua ^a   Shen, Li ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

CD133; EGFRvIII; Gefitinib resistance; Stemness

Indexed keywords

CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB;

ANIMAL EXPERIMENT; ARTICLE; ASTROCYTOMA; CANCER RESISTANCE; CANCER STEM CELL; CANCER TRANSPLANTATION; CARCINOGENESIS; CARCINOGENICITY; CELL COUNT; FEMALE; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE;

EID: 84879011160     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12092     Document Type: Article

References (47)

1. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-2172.
2. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res 1984;44:753-760.
3. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89:2965-2969.
4. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci USA 1992;89:4309-4913.
5. Malden LT, Novak U, Kaye AH, Burgess AW. Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Res 1998;48:2711-2714.
6. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990;87:8602-8606.
7. Yamazaki H, Fukui Y, Ueyama Y, et al. Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 1998;8:1816-1820.
8. Nishikawa R, Ji XD, Harmon RC, et al. Huang, A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91:7727-7731.
9. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signalling. J Biol Chem 1997;272:2927-2935.
10. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999;45:1442-1453.
11. Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res 2000;60:3081-3087.
12. Nagane M, Coufal F, Lin H, Bögler O, Cavenee WK, Huang HJ. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996;56:5079-5086.
13. Lammering G, Hewit TH, Valerie K, et al. EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 2003;22:5545-5553.
14. Weppler SA, Li Y, Dubois L, et al. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 2007;83:333-339.
15. Learn CA, Hartzell TL, Wikstrand CJ, et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant iii contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004;10:3216-3224.
16. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-5073.
17. Pillay V, Allaf L, Wilding AL, et al. The plasticity of Oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009;11:448-458.
18. Cao X, Zhu H, Ali-Osman F, Lo HW. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis. Mol Cancer 2011;10:26.
19. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-7021.
20. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
21. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004;23(58):9392-9400.
22. Yuan X, Curtin J, Xiong Y, et al. Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasivebreast carcinoma. Cancer Res 2012;72:2657-2671.
23. Ma HI, Chiou SH, Hueng DY, et al. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: Improvement in radiotherapeutic effects. Laboratory investigation. J Neurosurg 2011;114:651-662.
24. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133 + glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009;15:5145-5153.
25. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67:1-5.
26. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737.
27. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988.
28. Visvader JE, Lindeman GJ. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 2012;10:717-728.
29. Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK. CD44posCD49fhi CD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 2010;70:4624-4633.
30. Zhang WC, Shyh-Chang N, Yang H., et al. Glycine decarboxylase activity drives nonsmall cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012;148:259-272.
31. Silva IA, Bai S, McLean K, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells. Cancer Res 2011;71:3991-4001.
32. Lathia JD, Hitomi M, Gallagher J, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis 2011;2:e200.
33. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
34. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008;26:3008-3017.
35. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010-4015.
36. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010;17:362-375.
37. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumorinitiating cells. Proc Natl Acad Sci USA 2010;108:6468-6473.
38. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-611.
39. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008;14:135-145.
40. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), and inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892.
41. Ciardiello F, Caputo R, Bianco R, et al. Tortora inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-1465.
42. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Clin Cancer Res 2001;61:5790-5795.
43. Baselga J, Averbuch SD. ZD1839 ("Iressa") as an anticancer agent. Drugs 2000;60:33-40.
44. Heimberger AB, Learn CA, Archer GE, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 2002;8:3496-3502.
45. Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 2005;93:915-992.
46. Latha K, Li M, Chumbalkar V, et al. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int J Cancer 2013;132:509-520.
47. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024.